STOCK TITAN

OneMedNet flags going-concern doubt with $137K cash

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

OneMedNet Corp (ONMD) reported third-quarter 2026 revenue of $1.023 million, versus $177,000 a year earlier, while net loss widened to $2.660 million from $741,000. For the first nine months, revenue was $1.410 million versus $468,000, and net loss was $7.285 million versus net income of $339,000.

Cash and equivalents were $137,000 as of September 30, 2026, while operating activities used $4.839 million during the nine months. Management said cash was not adequate to fund operations through at least 12 months from issuance, raising substantial doubt about the company’s ability to continue as a going concern; it plans to raise working capital through equity or debt.

Under its 2026 agreement with Yorkville, the company may sell up to $25 million of common stock over 36 months, at its option and subject to conditions including an effective resale registration statement; Yorkville generally pays 97% of Market Price. Yorkville and affiliates may not exceed 4.99% beneficial ownership, and without stockholder approval, issuance is capped at 19.9% of common stock outstanding on July 1, 2026. A 1-for-10 reverse split took effect September 29, 2026.

1 point · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

2 major · 2 points

How the balance works

Positive

  • Moderate pointNine-month revenue increased 201% to $1.410 million.

Negative

  • Major pointCash of $137,000 was insufficient to fund operations through at least 12 months.
  • Major pointNine-month results shifted to a $7.285 million net loss from $339,000 net income.

Filing Explained

By September 30, the 10-Q documents 413,059 related-party shares and 135,387 SEPA shares issued; October subscriptions covered 174,884 shares.

This 10-Q reports that in the first nine months of 2026, OneMedNet issued 413,059 shares to two related-party investors for $3.1 million gross and 135,387 shares under its 2024 Yorkville equity agreement for $1.0 million gross.

Those issuances add to the common-share base and reduce existing holders’ percentage ownership absent offsetting changes; the 2024 Yorkville agreement expired in June 2026.

After quarter-end, OneMedNet entered into October subscription agreements covering 174,884 shares and received approximately $1.0 million in gross proceeds.

As of November 16, 2026, it reported 6,201,813 common shares issued and outstanding.

Third-quarter revenue $1.023 million Three months ended September 30, 2026; compared with $177,000 in 2025, a 478% increase.
Third-quarter net loss $2.660 million Three months ended September 30, 2026; compared with a $741,000 net loss in 2025.
Nine-month revenue $1.410 million Nine months ended September 30, 2026; compared with $468,000 in 2025, a 201% increase.
Nine-month net loss $7.285 million Nine months ended September 30, 2026; compared with $339,000 net income in 2025.
Cash and cash equivalents $137,000 As of September 30, 2026.
Net cash used in operating activities $4.839 million Nine months ended September 30, 2026.
2026 SEPA commitment Up to $25 million Common stock sales to Yorkville over a 36-month period, at the company’s option and subject to agreement conditions.
Largest customer share of revenue 54% Three months ended September 30, 2026.
iRWD technical
"proprietary iRWD platform"
real-world evidence medical
"real-world evidence generation"
Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.
going concern financial
"substantial doubt about the Company’s ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
standby equity purchase agreement financial
"Under the 2026 SEPA"
A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.
embedded put option financial
"includes an embedded put option"
anti-dilutive financial
"considered “anti-dilutive”"
A claim, security feature, or action described as anti-dilutive prevents or does not cause a reduction in existing shareholders’ per-share values when additional shares could be issued. For example, certain convertible securities or corporate actions are treated as anti-dilutive for earnings-per-share calculations if including them would raise EPS rather than lower it; investors watch this because it affects reported per-share metrics, ownership percentages, and valuation comparisons, like keeping pie slices the same size instead of making them smaller.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much revenue and net loss did ONMD report for Q3 2026?

ONMD reported $1.023 million in revenue and a $2.660 million net loss for the three months ended September 30, 2026. The comparable 2025 figures were $177,000 in revenue and a $741,000 net loss.

What are the terms of ONMD’s 2026 Yorkville equity agreement?

The 2026 agreement allows OneMedNet to sell Yorkville up to $25 million of common stock over 36 months, at the company’s option. Sales are subject to conditions including an effective resale registration statement covering applicable shares, and Yorkville generally pays 97% of the defined Market Price. Yorkville and its affiliates may not exceed 4.99% beneficial ownership; without stockholder approval, issuance is capped at 19.9% of common stock outstanding on July 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 Q3 0001849380 0001849380 2026-01-01 2026-09-30 0001849380 ONMD:CommonStockParValue0.0001PerShareMember 2026-01-01 2026-09-30 0001849380 ONMD:RedeemableWarrantsEachLotOf10WarrantsExercisableForOneShareOfCommonStockAtExercisePriceOf115.00PerShareMember 2026-01-01 2026-09-30 0001849380 2026-11-16 0001849380 2026-09-30 0001849380 2025-12-31 0001849380 2026-07-01 2026-09-30 0001849380 2025-07-01 2025-09-30 0001849380 2025-01-01 2025-09-30 0001849380 ONMD:SubscriptionRevenueMember 2026-07-01 2026-09-30 0001849380 ONMD:SubscriptionRevenueMember 2025-07-01 2025-09-30 0001849380 ONMD:SubscriptionRevenueMember 2026-01-01 2026-09-30 0001849380 ONMD:SubscriptionRevenueMember 2025-01-01 2025-09-30 0001849380 ONMD:DataDeliveryRevenueMember 2026-07-01 2026-09-30 0001849380 ONMD:DataDeliveryRevenueMember 2025-07-01 2025-09-30 0001849380 ONMD:DataDeliveryRevenueMember 2026-01-01 2026-09-30 0001849380 ONMD:DataDeliveryRevenueMember 2025-01-01 2025-09-30 0001849380 us-gaap:CommonStockMember 2025-12-31 0001849380 us-gaap:TreasuryStockCommonMember 2025-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001849380 us-gaap:RetainedEarningsMember 2025-12-31 0001849380 us-gaap:CommonStockMember 2026-03-31 0001849380 us-gaap:TreasuryStockCommonMember 2026-03-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001849380 us-gaap:RetainedEarningsMember 2026-03-31 0001849380 2026-03-31 0001849380 us-gaap:CommonStockMember 2026-06-30 0001849380 us-gaap:TreasuryStockCommonMember 2026-06-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001849380 us-gaap:RetainedEarningsMember 2026-06-30 0001849380 2026-06-30 0001849380 us-gaap:CommonStockMember 2024-12-31 0001849380 us-gaap:TreasuryStockCommonMember 2024-12-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001849380 us-gaap:RetainedEarningsMember 2024-12-31 0001849380 2024-12-31 0001849380 us-gaap:CommonStockMember 2025-03-31 0001849380 us-gaap:TreasuryStockCommonMember 2025-03-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001849380 us-gaap:RetainedEarningsMember 2025-03-31 0001849380 2025-03-31 0001849380 us-gaap:CommonStockMember 2025-06-30 0001849380 us-gaap:TreasuryStockCommonMember 2025-06-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001849380 us-gaap:RetainedEarningsMember 2025-06-30 0001849380 2025-06-30 0001849380 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001849380 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001849380 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001849380 2026-01-01 2026-03-31 0001849380 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001849380 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001849380 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001849380 2026-04-01 2026-06-30 0001849380 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001849380 us-gaap:TreasuryStockCommonMember 2026-07-01 2026-09-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001849380 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001849380 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001849380 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001849380 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001849380 2025-01-01 2025-03-31 0001849380 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001849380 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001849380 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001849380 2025-04-01 2025-06-30 0001849380 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001849380 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001849380 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001849380 us-gaap:CommonStockMember 2026-09-30 0001849380 us-gaap:TreasuryStockCommonMember 2026-09-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001849380 us-gaap:RetainedEarningsMember 2026-09-30 0001849380 us-gaap:CommonStockMember 2025-09-30 0001849380 us-gaap:TreasuryStockCommonMember 2025-09-30 0001849380 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001849380 us-gaap:RetainedEarningsMember 2025-09-30 0001849380 2025-09-30 0001849380 2026-09-29 2026-09-29 0001849380 2026-09-29 0001849380 srt:AmericasMember 2026-07-01 2026-09-30 0001849380 srt:AmericasMember 2025-07-01 2025-09-30 0001849380 srt:AmericasMember 2026-01-01 2026-09-30 0001849380 srt:AmericasMember 2025-01-01 2025-09-30 0001849380 ONMD:RestOfWorldMember 2026-07-01 2026-09-30 0001849380 ONMD:RestOfWorldMember 2025-07-01 2025-09-30 0001849380 ONMD:RestOfWorldMember 2026-01-01 2026-09-30 0001849380 ONMD:RestOfWorldMember 2025-01-01 2025-09-30 0001849380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ONMD:ThreeCustomersMember 2026-07-01 2026-09-30 0001849380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ONMD:ThreeCustomersMember 2026-01-01 2026-09-30 0001849380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ONMD:LargestCustomerMember 2026-07-01 2026-09-30 0001849380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ONMD:LargestCustomerMember 2026-01-01 2026-09-30 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:TwoCustomersMember 2026-07-01 2026-09-30 0001849380 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember ONMD:TwoCustomersMember 2025-01-01 2025-12-31 0001849380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ONMD:TwoCustomersMember 2025-07-01 2025-09-30 0001849380 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember ONMD:TwoCustomersMember 2025-01-01 2025-09-30 0001849380 2026-04-01 2026-04-30 0001849380 2026-04-30 0001849380 us-gaap:LoansPayableMember 2026-09-30 0001849380 us-gaap:LoansPayableMember 2025-12-31 0001849380 us-gaap:LongTermDebtMember 2026-09-30 0001849380 us-gaap:LongTermDebtMember 2025-12-31 0001849380 ONMD:StandbyEquityPurchaseAgreementMember 2026-01-01 2026-09-30 0001849380 ONMD:SEPAMember 2026-09-30 0001849380 ONMD:SEPAMember 2025-12-31 0001849380 us-gaap:CommonStockMember ONMD:SEPAMember 2026-01-01 2026-09-30 0001849380 ONMD:SEPAMember 2026-01-01 2026-09-30 0001849380 ONMD:SEPAMember 2025-07-01 2025-09-30 0001849380 ONMD:SEPAMember 2025-01-01 2025-09-30 0001849380 ONMD:TwoThousandTwentySixStandbyEquityPurchaseAgreementsMember 2026-07-01 2026-07-01 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember 2026-07-01 2026-07-01 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember 2026-01-01 2026-09-30 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember srt:MaximumMember 2026-07-01 2026-07-01 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember 2026-09-30 0001849380 ONMD:SubscriptionAgreementsMember 2026-02-01 2026-02-28 0001849380 ONMD:SubscriptionAgreementsMember 2026-09-01 2026-09-30 0001849380 ONMD:SubscriptionAgreementsMember 2026-02-28 0001849380 ONMD:SubscriptionAgreementsMember 2026-09-30 0001849380 ONMD:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2026-10-01 2026-10-31 0001849380 ONMD:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2026-10-31 0001849380 ONMD:SubscriptionAgreementsMember 2026-01-01 2026-09-30 0001849380 ONMD:ARCForwardContractMember 2026-01-01 2026-09-30 0001849380 ONMD:ARCForwardContractMember 2025-01-01 2025-12-31 0001849380 us-gaap:RestrictedStockMember 2026-07-01 2026-09-30 0001849380 us-gaap:RestrictedStockMember 2025-07-01 2025-09-30 0001849380 us-gaap:RestrictedStockMember 2026-01-01 2026-09-30 0001849380 us-gaap:RestrictedStockMember 2025-01-01 2025-09-30 0001849380 ONMD:WarrantCommonStockMember 2026-07-01 2026-09-30 0001849380 ONMD:WarrantCommonStockMember 2025-07-01 2025-09-30 0001849380 ONMD:WarrantCommonStockMember 2026-01-01 2026-09-30 0001849380 ONMD:WarrantCommonStockMember 2025-01-01 2025-09-30 0001849380 ONMD:ExtensionLoansMember 2026-07-01 2026-09-30 0001849380 ONMD:ExtensionLoansMember 2025-07-01 2025-09-30 0001849380 ONMD:ExtensionLoansMember 2026-01-01 2026-09-30 0001849380 ONMD:ExtensionLoansMember 2025-01-01 2025-09-30 0001849380 us-gaap:CostOfRevenue 2026-07-01 2026-09-30 0001849380 us-gaap:CostOfRevenue 2025-07-01 2025-09-30 0001849380 us-gaap:CostOfRevenue 2026-01-01 2026-09-30 0001849380 us-gaap:CostOfRevenue 2025-01-01 2025-09-30 0001849380 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001849380 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001849380 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001849380 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001849380 us-gaap:SellingAndMarketingExpense 2026-07-01 2026-09-30 0001849380 us-gaap:SellingAndMarketingExpense 2025-07-01 2025-09-30 0001849380 us-gaap:SellingAndMarketingExpense 2026-01-01 2026-09-30 0001849380 us-gaap:SellingAndMarketingExpense 2025-01-01 2025-09-30 0001849380 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0001849380 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0001849380 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0001849380 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0001849380 us-gaap:ShareBasedCompensation 2026-07-01 2026-09-30 0001849380 us-gaap:ShareBasedCompensation 2025-07-01 2025-09-30 0001849380 us-gaap:ShareBasedCompensation 2026-01-01 2026-09-30 0001849380 us-gaap:ShareBasedCompensation 2025-01-01 2025-09-30 0001849380 ONMD:LiabilityClassifiedWarrantsMember ONMD:BusinessCombinationWarrantsMember 2026-09-30 0001849380 ONMD:LiabilityClassifiedWarrantsMember ONMD:BusinessCombinationWarrantsMember 2025-12-31 0001849380 ONMD:LiabilityClassifiedWarrantsMember ONMD:PIPEWarrantsMember 2026-09-30 0001849380 ONMD:LiabilityClassifiedWarrantsMember ONMD:PIPEWarrantsMember 2025-12-31 0001849380 ONMD:LiabilityClassifiedWarrantsMember 2026-09-30 0001849380 ONMD:LiabilityClassifiedWarrantsMember 2025-12-31 0001849380 ONMD:EquityClassifiedWarrantsMember ONMD:PublicWarrantsMember 2026-09-30 0001849380 ONMD:EquityClassifiedWarrantsMember ONMD:PublicWarrantsMember 2025-12-31 0001849380 ONMD:EquityClassifiedWarrantsMember ONMD:PrivatePlacementWarrantsMember 2026-09-30 0001849380 ONMD:EquityClassifiedWarrantsMember ONMD:PrivatePlacementWarrantsMember 2025-12-31 0001849380 ONMD:EquityClassifiedWarrantsMember 2026-09-30 0001849380 ONMD:EquityClassifiedWarrantsMember 2025-12-31 0001849380 us-gaap:CommonStockMember 2026-06-30 2026-06-30 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2026-09-30 0001849380 us-gaap:MoneyMarketFundsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BusinessCombinationWarrantsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BusinessCombinationWarrantsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BusinessCombinationWarrantsMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ONMD:PIPEWarrantsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ONMD:PIPEWarrantsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ONMD:PIPEWarrantsMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember 2026-09-30 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-12-31 0001849380 us-gaap:MoneyMarketFundsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BitcoinMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BitcoinMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BitcoinMember 2025-12-31 0001849380 ONMD:BitcoinMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BusinessCombinationWarrantsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BusinessCombinationWarrantsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ONMD:BusinessCombinationWarrantsMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ONMD:PIPEWarrantsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ONMD:PIPEWarrantsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ONMD:PIPEWarrantsMember 2025-12-31 0001849380 ONMD:PIPEWarrantsMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ONMD:StandbyEquityPurchaseAgreementPutOptionLiabilityMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember ONMD:StandbyEquityPurchaseAgreementPutOptionLiabilityMember 2025-12-31 0001849380 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember ONMD:StandbyEquityPurchaseAgreementPutOptionLiabilityMember 2025-12-31 0001849380 ONMD:StandbyEquityPurchaseAgreementPutOptionLiabilityMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember 2026-01-01 2026-03-31 0001849380 ONMD:PIPEWarrantsMember 2026-01-01 2026-03-31 0001849380 ONMD:BusinessCombinationWarrantsMember 2026-03-31 0001849380 ONMD:PIPEWarrantsMember 2026-03-31 0001849380 ONMD:BusinessCombinationWarrantsMember 2026-04-01 2026-06-30 0001849380 ONMD:PIPEWarrantsMember 2026-04-01 2026-06-30 0001849380 ONMD:BusinessCombinationWarrantsMember 2026-06-30 0001849380 ONMD:PIPEWarrantsMember 2026-06-30 0001849380 ONMD:BusinessCombinationWarrantsMember 2026-07-01 2026-09-30 0001849380 ONMD:PIPEWarrantsMember 2026-07-01 2026-09-30 0001849380 ONMD:StandbyEquityPurchaseAgreementForwardOptionLiabilityMember 2025-12-31 0001849380 ONMD:StandbyEquityPurchaseAgreementPutOptionLiabilityMember 2026-01-01 2026-09-30 0001849380 ONMD:StandbyEquityPurchaseAgreementForwardOptionLiabilityMember 2026-01-01 2026-09-30 0001849380 ONMD:StandbyEquityPurchaseAgreementPutOptionLiabilityMember 2026-09-30 0001849380 ONMD:StandbyEquityPurchaseAgreementForwardOptionLiabilityMember 2026-09-30 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember 2025-12-31 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember 2026-01-01 2026-09-30 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputExercisePriceMember 2025-12-31 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2025-12-31 0001849380 ONMD:PIPEWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001849380 ONMD:BusinessCombinationWarrantsMember us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001849380 us-gaap:MeasurementInputExpectedTermMember 2025-12-31 0001849380 us-gaap:MeasurementInputSharePriceMember 2025-12-31 0001849380 us-gaap:MeasurementInputPriceVolatilityMember 2025-12-31 0001849380 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-12-31 0001849380 us-gaap:MeasurementInputExpectedTermMember 2026-09-30 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember us-gaap:MeasurementInputSharePriceMember 2026-09-30 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember us-gaap:MeasurementInputPriceVolatilityMember 2026-09-30 0001849380 ONMD:TwoThousandAndTwentySixStandbyEquityPurchaseAgreementMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-09-30 0001849380 srt:OfficerMember us-gaap:InvestorMember 2026-04-01 2026-04-30 0001849380 srt:ChiefFinancialOfficerMember 2026-07-01 2026-09-30 0001849380 srt:ChiefFinancialOfficerMember 2026-01-01 2026-09-30 0001849380 srt:ChiefFinancialOfficerMember 2025-07-01 2025-09-30 0001849380 srt:ChiefFinancialOfficerMember 2025-01-01 2025-09-30 0001849380 ONMD:ChiefTechnologyOfficerMember 2026-07-01 2026-09-30 0001849380 ONMD:ChiefTechnologyOfficerMember 2026-01-01 2026-09-30 0001849380 ONMD:ChiefTechnologyOfficerMember 2025-07-01 2025-09-30 0001849380 ONMD:ChiefTechnologyOfficerMember 2025-01-01 2025-09-30 0001849380 ONMD:ChiefTechnologyOfficerMember 2026-09-30 0001849380 ONMD:ChiefTechnologyOfficerMember 2025-12-31 0001849380 ONMD:ARCMember 2025-01-01 2025-12-31 0001849380 ONMD:ARCMember 2025-12-31 0001849380 ONMD:SubscriptionAgreementsMember us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2026-10-01 2026-10-31 0001849380 ONMD:SubscriptionAgreementsMember us-gaap:SubsequentEventMember 2026-10-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure ONMD:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026

OR

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

FOR THE TRANSITION PERIOD FROM TO

 

Commission File Number 001-40386

 

ONEMEDNET CORPORATION

(Exact name of Registrant as specified in its Charter)

 

Delaware   86-2076743

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

6385 Old Shady Oak Road, Suite 250

Eden Prairie, Minnesota

  55344
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (800) 918-7189

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.0001 per share   ONMD   The Nasdaq Stock Market LLC
Redeemable Warrants, each lot of 10 warrants exercisable for one share of Common Stock at an exercise price of $115.00 per share   ONMDW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
       
Non-accelerated filer ☒ Smaller reporting company ☒
       
Emerging growth company ☒    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 16, 2026, there were 6,201,813 shares of common stock, par value $0.0001 per share, issued and outstanding.

 

 

 

 

 

 

Table of Contents

 

      Page
       
  CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS   ii
       
PART I. FINANCIAL INFORMATION    
       
Item 1. Condensed Consolidated Financial Statements   1
  Unaudited Condensed Consolidated Balance Sheets as of September 30, 2026 and December 31, 2025   1
  Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2026 and 2025   2
  Unaudited Condensed Consolidated Statements of Changes in Stockholders’ Deficit for the three and nine months ended September 30, 2026 and 2025   3
  Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2026 and 2025   5
  Notes to Unaudited Condensed Consolidated Financial Statements   6
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   19
Item 3. Quantitative and Qualitative Disclosures About Market Risk   27
Item 4. Controls and Procedures   27
       
PART II. OTHER INFORMATION    
       
Item 1. Legal Proceedings   28
Item 1A. Risk Factors   28
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   29
Item 3. Defaults Upon Senior Securities   29
Item 4. Mine Safety Disclosures   29
Item 5. Other Information   29
Item 6. Exhibits   29
Signature   30

 

i

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain statements that we make from time to time, including statements contained in this Quarterly Report on Form 10-Q (this “Report”) constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, and of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Report are forward-looking statements. The forward-looking statements in this Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. In some cases, you can identify these forward-looking statements by terms such as “anticipate,” “believe,” “continue,” “could,” “depends,” “estimate,” “expects,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words. These forward-looking statements are based on our current expectations and projections regarding future events and trends that may affect our financial condition, results of operations, strategy, business objectives, and financial needs.

 

Our operations involve risks and uncertainties, many of which are outside our control, and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. Forward-looking statements in this Report include, without limitation, statements reflecting management’s expectations regarding future financial performance and operating expenditures (including our ability to continue as a going concern, to raise additional capital and to succeed in our future operations), expected growth, profitability and business outlook, liquidity, operating expenses, and enhancement of our internal control structure.

 

Forward-looking statements are only current predictions and are subject to known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. These factors include, among other things, the unknown risks and uncertainties that we believe could cause actual results to differ from these forward looking statements as set forth under the heading, “Risk Factors” and elsewhere in this Report and other documents we file with the SEC. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to:

 

  ● our projected financial position and estimated cash burn rate;
     
  ● our estimates regarding expenses, future revenues and capital requirements;
     
  ● our ability to continue as a going concern;
     
  ● our ability to raise substantial additional capital in sufficient amounts or on acceptable terms to fund our operations and our business plan;
     
  ● our ability to reverse the recent decline in our revenue and resume growing our revenue;
     
  ● our ability to obtain and maintain intellectual property protection for our current products and services;

 

ii

 

 

  ● our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;
     
  ● the possibility that a third party may claim we have infringed, misappropriated or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against these claims;
  ● our reliance on third-party suppliers;
     
  ● the success of competing products or services that are or become available;
     
  ● our ability to expand our organization to accommodate potential growth and our ability to retain and attract key personnel;
     
  ● the potential for us to incur substantial costs resulting from lawsuits against us and the potential for these lawsuits to cause us to limit our commercialization of our products and services; and
     
  ● changes in demand for our products and services as a result of geopolitical and/or macroeconomic conditions.

 

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents we file with the Securities and Exchange Commission. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Report to conform these statements to actual results or to changes in our expectations.

 

You should read this Report and the documents that we incorporate by reference in this Form 10-Q with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements including those described in this Report and in the “Risk Factors” section of our Annual Report on Form 10-K and other documents we file with the Securities and Exchange Commission.

 

iii

 

 

PART I—FINANCIAL INFORMATION

 

Item 1. Condensed Consolidated Financial Statements

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

    September 30, 2026     December 31, 2025  
    (unaudited)        
Assets                
Current assets:                
Cash and cash equivalents   $ 137     $ 585  
Investment in crypto assets – Bitcoin     -       506  
Accounts receivable, net     2,272       495  
Prepaid expenses and other current assets     156       509  
Total current assets     2,565       2,095  
Property and equipment, net     44       56  
Total assets   $ 2,609     $ 2,151  
Liabilities and stockholders’ deficit                
Current liabilities:                
Accounts payable and accrued expenses   $ 4,504     $ 3,496  
Deferred revenue     1,481       389  
Loans payable     464       754  
Advance from investor – related party     250       -  
2024 SEPA put option liability     -       186  
Total current liabilities     6,699       4,825  
2026 SEPA put option liability     436       -  
Loans payable, net of current portion     99       220  
Warrant liabilities     5       71  
Total liabilities     7,239       5,116  
Commitments and contingencies (Note 14)     -       -  
Stockholders’ deficit:                
Preferred Stock, par value $0.0001, 1,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025     -       -  
Common Stock, par value $0.0001, 100,000,000 shares authorized, 6,045,672 shares issued and 6,026,897 shares outstanding at September 30, 2026, and 5,198,464 shares issued and 5,179,689 shares outstanding at December 31, 2025     1       1  
Additional paid-in capital     107,553       101,933  
Treasury stock, at cost, 18,775 shares at September 30, 2026 and December 31, 2025     (529 )     (529 )
Accumulated deficit     (111,655 )     (104,370 )
Total stockholders’ deficit     (4,630 )     (2,965 )
Total liabilities and stockholders’ deficit   $ 2,609     $ 2,151  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except share and per share data)

(Unaudited)

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Revenue                    
Subscription revenue  $-   $-   $-   $105 
Data delivery revenue   1,023    177    1,410    363 
Total revenue   1,023    177    1,410    468 
Cost of revenue   1,386    399    2,928    1,136 
Gross margin   (363)   (222)   (1,518)   (668)
Operating expenses                    
General and administrative   1,185    1,386    3,439    3,999 
Sales and marketing   262    304    1,031    846 
Research and development   424    323    1,059    1,072 
Total operating expenses   1,871    2,013    5,529    5,917 
Loss from operations   (2,234)   (2,235)   (7,047)   (6,585)
Other expense (income), net                    
Interest expense   8    6    27    59 
Change in fair value of warrants   (19)   20    (66)   23 
Change in fair value of convertible notes   -    -    -    (1,285)
Change in fair value of crypto assets – Bitcoin   -    (55)   (147)   782 
Realized loss (gain) on sale of crypto assets – Bitcoin   -    (54)   234    (899)
Change in fair value of 2024 SEPA derivative liabilities   -    402    (245)   (32)
Change in fair value of 2026 SEPA derivative liabilities   436    -    436    - 
Gain on troubled debt restructurings   -    (1,862)   -    (5,569)
Loss on extinguishment of debt   -    41    -    41 
Other expense (income)   1    8    (1)   (44)
Total other expense (income), net   426    (1,494)   238    (6,924)
Net (loss) income  $(2,660)  $(741)  $(7,285)  $339 
Net (loss) income per share attributable to common shares – basic  $(0.43)  $(0.14)  $(1.25)  $0.08 
Weighted average shares of common stock outstanding – basic   6,148,636    5,261,803    5,837,487    4,125,372 
Net (loss) income per share attributable to common shares – diluted  $(0.43)  $(0.14)  $(1.25)  $0.08 
Weighted average shares of common stock outstanding – diluted   6,148,636    5,261,803    5,837,487    4,297,491 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN

STOCKHOLDERS’ DEFICIT

(In thousands, except share data)

(Unaudited)

 

Three and Nine Months Ended September 30, 2026

 

   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
           Additional       Total 
   Common Stock   Treasury Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balances as of December 31, 2025   5,198,464   $1    (18,775)  $(529)  $101,933   $(104,370)  $(2,965)
Issuance of common stock in connection with 2024 SEPA   40,000    -    -    -    408    -    408 
Issuance of common stock in connection with subscription agreement with related party   59,524    -    -    -    500    -    500 
Stock-based compensation expense   -    -    -    -    431    -    431 
Net loss   -    -    -    -    -    (2,453)   (2,453)
Balances as of March 31, 2026   5,297,988    1    (18,775)   (529)   103,272    (106,823)   (4,079)
Issuance of common stock in connection with 2024 SEPA   95,387    -    -    -    495    -    495 
Issuance of common stock in connection with subscription agreements with related parties   194,321    -    -    -    1,550    -    1,550 
Conversion of officer accrued salary into shares of common stock   21,943    -    -    -    182    -    182 
Issuance of common stock in connection with exercise of pre-funded warrants   67,754    -    -    -    -    -    - 
Issuance of common stock in connection with exercise of warrants   13,310    -    -    -    43    -    43 
Vesting of restricted stock units   100,225    -    -    -    -    -    - 
Stock-based compensation expense   -    -    -    -    463    -    463 
Net loss   -    -    -    -    -    (2,172)   (2,172)
Balances as of June 30, 2026   5,790,928    1    (18,775)   (529)   106,005    (108,995)   (3,518)
Issuance of common stock in connection with subscription agreements with related parties   159,214    -    -    -    1,090    -    1,090 
Vesting of restricted stock units   95,530    -    -    -    -    -    - 
Stock-based compensation expense   -    -    -    -    458    -    458 
Net loss   -    -    -    -    -    (2,660)   (2,660)
Balances as of September 30, 2026   6,045,672   $1    (18,775)  $(529)  $107,553   $(111,655)  $(4,630)

 

3

 

 

Three and Nine Months Ended September 30, 2025

 

           Additional       Total 
   Common Stock   Treasury Stock   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Capital   Deficit   Deficit 
Balances as of December 31, 2024   2,817,528   $1    (18,775)  $(529)  $86,147   $(101,569)  $(15,950)
Issuance of common stock in connection with September 2024 private placement   147,370    -    -    -    -    -    - 
Issuance of common stock upon partial conversion of Yorkville Note   111,171    -    -    -    1,094    -    1,094 
Stock-based compensation expense   -    -    -    -    208    -    208 
Net loss   -    -    -    -    -    (1,902)   (1,902)
Balances as of March 31, 2025   3,076,069    1    (18,775)   (529)   87,449    (103,471)   (16,550)
Issuance of common stock in connection with settlement of vendor payable   25,000    -    -    -    111    -    111 
Issuance of common stock upon partial conversion of Yorkville Note   75,486    -    -    -    298    -    298 
Issuance of common stock upon conversion of loans with related parties   316,648    -    -    -    2,334    -    2,334 
Issuance of common stock upon conversion of PIPE Notes   145,318    -    -    -    510    -    510 
Issuance of common stock upon conversion of loan extensions with related parties   365,025    -    -    -    2,584    -    2,584 
Issuance of common stock in connection with June 2025 private placement   339,093    -    -    -    2,497    -    2,497 
                                    
Issuance of common stock in connection with subscription agreements with related parties   285,715    -    -    -    1,197    -    1,197 
Stock-based compensation expense   -    -    -    -    197    -    197 
Net income   -    -    -    -    -    2,982    2,982 
                                    
Balances as of June 30, 2025   4,628,354    1    (18,775)   (529)   97,177    (100,489)   (3,840)
Issuance of common stock in connection with pre-funded warrant exercises   304,824    -    -    -    -    -    - 
Issuance of common stock in connection with subscription agreement with related party   58,140    -    -    -    500    -    500 
Stock-based compensation expense   -    -    -    -    142    -    142 
Net loss   -    -    -    -    -    (741)   (741)
Balances as of September 30, 2025   4,991,318   $1    (18,775)  $(529)  $97,819   $(101,230)  $(3,939)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

 

ONEMEDNET CORPORATION

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

 

   2026   2025 
   Nine Months Ended September 30, 
   2026   2025 
Cash flows from operating activities:          
Net (loss) income  $(7,285)  $339 
Adjustments to reconcile net (loss) income to net cash used in operating activities:          
Depreciation and amortization   24    56 
Stock-based compensation expense   1,352    547 
Change in fair value of warrants   (66)   23 
Change in fair value of convertible notes   -    (1,285)
Change in fair value of crypto assets – Bitcoin   (147)   782 
Change in fair value of 2024 SEPA derivative liabilities   (245)   (32)
Change in fair value of 2026 SEPA derivative liabilities   436    - 
Realized loss (gain) on sale of crypto assets – Bitcoin   234    (899)
Gain on troubled debt restructurings   -    (5,569)
Loss on extinguishment of debt   -    41 
Non-cash interest   -    45 
Change in operating assets and liabilities:          
Accounts receivable   (1,777)   (369)
Prepaid expenses and other current assets   353    270 
Accounts payable and accrued expenses   1,190    387 
Deferred revenue   1,092    209 
Net cash used in operating activities   (4,839)   (5,455)
Cash flows from investing activities:          
Purchases of property and equipment   (12)   (8)
Purchases of crypto assets – Bitcoin   -    (2,400)
Sales of crypto assets – Bitcoin   419    4,766 
Net cash provided by investing activities   407    2,358 
Cash flows from financing activities:          
Proceeds from 2024 SEPA   962    - 
Proceeds from subscription agreements with related parties   3,140    1,697 
Proceeds from investor advance – related party   250    - 
Proceeds from exercise of warrants   43    - 
Proceeds from private placement   -    2,497 
Repayment of Yorkville Note   -    (262)
Repayment of deferred underwriter fees payable   -    (500)
Repayment of loans payable   (411)   (358)
Net cash provided by financing activities   3,984    3,074 
Net decrease in cash and cash equivalents   (448)   (23)
Cash and cash equivalents at beginning of period   585    172 
Cash and cash equivalents at end of period  $137   $149 
Supplemental disclosures of cash flow information:          
Cash paid for interest  $27   $33 
Cash paid for taxes  $1   $- 
Supplemental disclosures of non-cash investing and financing activities:          
Conversion of officer accrued salary into shares of common stock  $182   $- 
Issuance of common stock in connection with settlement of vendor payable  $-   $111 
Issuance of common stock upon conversion of convertible notes  $-   $1,902 
Issuance of common stock upon conversion of loans with related parties  $-   $2,334 
Issuance of common stock upon conversion of loan extensions with related parties  $-   $2,584 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

5

 

 

ONEMEDNET CORPORATION

 

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

1. Description of Business

 

Organization and Description of Business

 

OneMedNet Corporation (the “Company”) is a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through its proprietary iRWD™ platform and network of healthcare providers, the Company provides pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.

 

The Company’s platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. The Company combines its technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.

 

The Company was incorporated in Delaware on November 20, 2015 and is headquartered in Eden Prairie, Minnesota. The Company has one wholly owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated under the Business Corporations Act (British Columbia).

 

On November 7, 2023, Data Knights Merger Sub, Inc., a wholly owned subsidiary of Data Knights Acquisition Corp., merged with and into OneMedNet Solutions Corporation (formerly named OneMedNet Corporation), with OneMedNet Solutions Corporation surviving as a wholly owned subsidiary. Following the consummation of the transaction, Data Knights Acquisition Corp. was renamed OneMedNet Corporation.

 

Basis of Presentation and Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim reporting. As permitted under those rules and regulations, certain notes or other financial information normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. The interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal, recurring adjustments that are necessary to present fairly the Company’s results for the interim periods presented. The results from operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results to be expected for the year ending December 31, 2026, or for any future annual or interim period.

 

The accompanying interim unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes for the year ended December 31, 2025 in the Company’s Annual Report on Form 10-K, filed with the SEC on March 30, 2026 (the “Form 10-K”).

 

The interim unaudited condensed consolidated financial statements include the consolidated accounts of the Company’s wholly owned subsidiary, OneMedNet Technologies (Canada) Inc. All significant intercompany transactions have been eliminated in consolidation.

 

Reverse Stock Split

 

At the Company’s 2026 annual meeting of stockholders held on September 18, 2026, the Company’s stockholders approved a proposal to effect a reverse stock split of the Company’s common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.

 

On September 29, 2026, the Company effected a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 10 shares of the Company’s Common Stock issued and outstanding were automatically converted into one new share of Common Stock. Proportionate adjustments were also made to the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity awards. The Reverse Stock Split did not decrease the number of authorized shares of Common Stock and preferred stock or otherwise affect the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share for stockholders of record who would be entitled to receive fractional shares pursuant to the Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company effecting the Reverse Stock Split..

 

All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company’s outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.

 

Liquidity and Going Concern

 

The Company has incurred recurring net losses since its inception, including $2.7 million and $0.7 million for the three months ended September 30, 2026 and 2025, respectively. In addition, the Company had an accumulated deficit of $111.7 million as of September 30, 2026. The Company’s cash balance of $0.1 million is not adequate to fund its operations through at least 12 months from the date these condensed consolidated financial statements were issued. Therefore, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.

 

6

 

 

To continue and expand its operations, the Company will be required to, and management plans to, raise additional working capital through equity or debt offerings and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to raise capital and to achieve positive cash flow from operations.

 

Risks and Uncertainties

 

The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.

 

In addition, the Company has previously invested in Bitcoin, which is a crypto asset. Crypto assets are loosely regulated and there is no central marketplace for currency exchange. Supply is determined by a computer code, not by a central bank, and prices have been extremely volatile. Certain crypto asset exchanges have been closed due to fraud, failure or security breaches. Any of the Company’s crypto assets that reside on an exchange that shuts down may be lost. Several factors may affect the price of crypto assets, including, but not limited to: supply and demand, investors’ expectations with respect to the rate of inflation, interest rates, currency exchange rates or future regulatory measures (if any) that restrict the trading of crypto assets, and the use of crypto assets as a form of payment. There is no assurance that crypto assets will maintain their long-term value in terms of purchasing power in the future, or that acceptance of crypto asset payments by mainstream retail merchants and commercial businesses will continue to grow.

 

As crypto assets have grown in popularity and market size, various countries and jurisdictions have begun to develop regulations governing the crypto asset industry. To the extent future regulatory actions or policies limit the ability to exchange crypto assets or utilize them for payments, the demand for crypto assets could be reduced. Furthermore, regulatory actions may limit the ability of end-users to convert crypto assets into fiat currency (e.g., U.S. dollars) or use crypto assets to pay for goods and services. Such regulatory actions or policies could result in a reduction of demand, and in turn, a decline in the underlying crypto asset unit prices.

 

The effect of any future regulatory change on crypto assets in general is impossible to predict, but such change could be substantial and adverse to the Company and the value of the Company’s investments in crypto assets.

 

Crypto assets are not insured or protected under the Federal Deposit Insurance Corporation (“FDIC”) or the Securities Investor Protection Corporation (“SIPC”). Accordingly, with respect to its historical Bitcoin investment, the Company did not enjoy the protections of other assets covered by the FDIC or SIPC. As of September 30, 2026, the Company no longer held any Bitcoin or other crypto assets.

 

2. Summary of Significant Accounting Policies

 

Except as described below, the accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Form 10-K, and the accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies therein.

 

7

 

 

Reclassification

 

Certain prior period amounts have been reclassified to conform to the current year presentation. These reclassifications had no impact on the Company’s net loss, net cash flows, or stockholders’ deficit.

 

Accounting Pronouncements Not Yet Adopted

 

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the consolidated financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2024-03 on the presentation of its condensed consolidated financial statements and footnotes.

 

The Company has reviewed other recently issued accounting pronouncements and concluded that either they are not applicable to the business or no material effect is expected upon future adoption.

 

3. Segment Information

 

Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker (“CODM”), or decision-making group, in deciding how to allocate resources and in assessing performance. The Company considers its chief executive officer to be the Company’s CODM. The CODM manages its operations and allocates resources based on the Company’s consolidated results and therefore operates as one segment.

 

The Company’s operations consist of its real-world data (“RWD”) platform, which enables life sciences and healthcare customers to access curated clinical and imaging datasets. The Company decommissioned its legacy BEAM platform in May 2025 as part of its strategic transition to a unified real-world data platform. Revenue associated with the BEAM platform was generated through the date of decommissioning and will not continue in future periods.

 

The Company’s method for measuring segment profitability is operating loss, which the CODM uses to assess performance and make decisions for resource allocation, consistent with the measurement principles for operating loss as reported on the Company’s condensed consolidated statements of operations. The CODM uses consolidated operating loss to set budgets, evaluate margins, review actual results, and to make decisions whether to engage in capital management transactions.

 

The significant expenses regularly reviewed by the CODM are consistent with those reported on the Company’s condensed consolidated statements of operations, and expenses are not regularly reviewed on a more disaggregated basis for purposes of assessing segment performance and deciding how to allocate resources.

 

The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the Company’s condensed consolidated statements of operations. See Note 4 for revenue by geographic location.

 

8

 

 

4. Revenue

 

The Company’s disaggregation of revenue by major product offering is consistent with its presentation on the condensed consolidated statements of operations. Data delivery revenue is recognized at a point in time. Subscription revenue, which ceased following the decommissioning of the BEAM platform in May 2025, was recognized over time. The following table presents revenue by geographic region, based on the location of the customer (in thousands):

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Americas  $919   $99   $1,051   $272 
Rest of World   104    78    359    196 
Total  $1,023   $177   $1,410   $468 

 

Contract Balances

 

Accounts receivable, net includes unbilled receivables of $0.9 million and $0.2 million as of September 30, 2026 and December 31, 2025, respectively. The Company had no allowance for credit losses as of September 30, 2026 or December 31, 2025, and there was no activity in the allowance during the three and nine months ended September 30, 2026 and 2025. Unbilled receivables arise when data delivery revenue is recognized before the customer is invoiced and the Company’s right to consideration is unconditional, such that only the passage of time is required before payment is due. The Company had no contract assets as of September 30, 2026 or December 31, 2025.

 

Deferred revenue consists of amounts invoiced or received before data is delivered to and accepted by the customer and is recognized as revenue upon the customer’s acceptance of the data. The increase in deferred revenue from December 31, 2025 to September 30, 2026 was primarily due to advance billings under iRWD contracts for which data had not been delivered as of September 30, 2026. The beginning deferred revenue balances as of December 31, 2025 and December 31, 2024 were $0.4 million and $0.6 million, respectively. During the nine months ended September 30, 2026 and 2025, the Company recognized revenue of $0.1 million and $0.2 million, respectively, that was included in deferred revenue at the beginning of the respective periods.

 

Remaining Performance Obligations

 

The Company’s remaining performance obligations consist of the delivery of contracted data units under iRWD contracts, which are recognized as revenue upon the customer’s acceptance of the data. The Company has elected the practical expedient in ASC 606-10-50-14 not to disclose the value of remaining performance obligations for contracts with an original expected duration of one year or less. For the remaining contracts, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied and expected to be recognized beyond 12 months is not material.

 

Customer Concentration

 

For the three and nine months ended September 30, 2026, three customers each accounted for 10% or more of total revenue, together representing 81% and 59% of total revenue, respectively. The largest customer represented 54% and 39% of total revenue for the respective periods. As of September 30, 2026, two customers each accounted for 10% or more of accounts receivable, net, together representing 44% of the total balance. As of December 31, 2025, three customers each accounted for 10% or more of accounts receivable, net, together representing 51% of the total balance. The loss of, or a significant reduction in business from, any of these customers could have a material adverse effect on the Company’s results of operations, financial condition, and liquidity.

 

For the three and nine months ended September 30, 2025, five and two customers, respectively, each accounted for 10% or more of total revenue, together representing 76% and 26% of total revenue, respectively.

 

9

 

 

5. Crypto Assets Held

 

The Company’s crypto assets are comprised solely of Bitcoin. In accordance with ASC Topic 820, Fair Value Measurement, the Company measures the fair value of its Bitcoin based on the quoted end-of-day price on the measurement date for a single Bitcoin on an active trading platform, River.com. Management has determined that River.com, an active exchange market, represents a principal market for Bitcoin and the end-of-day quoted price is both readily available and representative of fair value (Level 1 inputs). The following table sets forth the units held, cost basis, and fair value of its investments in crypto assets, as shown on the condensed consolidated balance sheets as of December 31, 2025 (in thousands):

 

   December 31, 2025 
   Units   Cost Basis   Fair Value 
Crypto assets held:               
Bitcoin   6   $653   $506 
Total   6   $653   $506 

 

There were no crypto assets held by the Company as of September 30, 2026.

 

The following table presents a reconciliation of the fair values of the Company’s investments in crypto assets for the nine months ended September 30, 2026 (in thousands):

 

   Bitcoin 
Balance, December 31, 2025  $506 
Dispositions   (653)
Unrealized gain, net   147 
Balance, September 30, 2026  $- 

 

For the nine months ended September 30, 2026, the Company had Bitcoin dispositions of $0.7 million (including realized loss of $0.2 million). There was no Bitcoin activity for the three months ended September 30, 2026. Dispositions are the result of sales of Bitcoin. The Company uses a first-in, first-out methodology to assign costs to Bitcoin for purposes of the Bitcoin held and realized gains and losses disclosure above. Bitcoin is included in current assets in the condensed consolidated balance sheets due to the Company’s ability to sell them in a highly liquid marketplace and its intent to liquidate its Bitcoin to support operations when needed.

 

6. Accounts Payable and Accrued Expenses

 

Accounts payable and accrued expenses consisted of the following (in thousands):

 

   September 30, 2026   December 31, 2025 
   As of 
   September 30, 2026   December 31, 2025 
Professional fees  $1,779   $1,611 
Software and technology   1,223    682 
Payroll liabilities   538    730 
Data provider costs   868    356 
Other   96    117 
Total  $4,504   $3,496 

 

10

 

 

In April 2026, the Company issued 21,943 shares of its Common Stock at a price of $8.30 per share in exchange for the settlement of approximately $0.2 million of unpaid cash salary due to an officer and related party investor of the Company. The transaction was accounted for as a capital transaction with a related party and no gain or loss was recognized. As such, the net carrying value of $0.2 million was reclassified to stockholders’ deficit in the condensed consolidated balance sheets at the time of the conversion.

 

7. Debt

 

The following table summarizes outstanding debt for the periods indicated (in thousands):

 

   September 30, 2026   December 31, 2025 
   As of 
   September 30, 2026   December 31, 2025 
Loans payable          
Stock repurchase loan  $125   $118 
Insurance premium loan   -    286 
Extension loans   339    350 
Loans payable   464    754 
Long-term loans payable          
Extension loans   -    26 
Stock repurchase loan   99    194 
Long- term loans payable   99    220 
Total  $563   $974 

 

8. Stockholders’ Deficit

 

2024 SEPA Draws

 

As further described in the Form 10-K, the Company entered into a Standby Equity Purchase Agreement (“2024 SEPA”) with YA II PN, LTD, a Cayman Islands exempt limited company (“Yorkville”), on June 17, 2024. Under the 2024 SEPA, the Company has the right to sell to Yorkville up to $25.0 million of its Common Stock, subject to certain limitations and conditions set forth in the 2024 SEPA, from time to time, over a 24-month period. The 2024 SEPA was accounted for as a liability under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized at inception and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock.

 

The commitment period under the 2024 SEPA expired in June 2026 and, therefore, the derivative liability was $0 at September 30, 2026. The fair value of the derivative liability related to the embedded put option was estimated at $0.2 million at December 31, 2025, which was classified within short-term liabilities on the condensed consolidated balance sheets because the commitment period expires in less than one year.

 

During the nine months ended September 30, 2026, the Company delivered four advance notices for the sale of 135,387 shares of its Common Stock, resulting in cumulative gross proceeds of $1.0 million. A derivative asset for each embedded forward option was initially recorded at fair value upon delivery of each advance notice, which was subsequently remeasured with changes in fair value recorded in the condensed consolidated statements of operations until settlement. The Company recognized a gain of $0.1 million related to embedded forward options during the nine months ended September 30, 2026. The embedded forward option was deemed to have no value at December 31, 2025 as there were no outstanding notices for the sale of the Company’s Common Stock. During the nine months ended September 30, 2025, the Company did not deliver any advance notices under the 2024 SEPA.

 

The estimated issuance date fair value and remeasurement adjustments for the embedded put and forward options are presented within other expense (income), net under the caption change in fair value of 2024 SEPA derivative liabilities in the accompanying condensed consolidated statements of operations. The embedded put option resulted in a fair value gain of $0.2 million for the nine months ended September 30, 2026, a fair value loss of $0.4 million for the three months ended September 30, 2025, and a fair value gain of $0.03 million for the nine months ended September 30, 2025. The embedded forward option resulted in a fair value gain of $0.1 million for the nine months ended September 30, 2026, with no fair value adjustment for the three or nine months ended September 30, 2025. There was no activity under the 2024 SEPA during the three months ended September 30, 2026, as the facility expired in June 2026.

 

11

 

 

2026 SEPA

 

On July 1, 2026, the Company entered into a separate standby equity purchase agreement (the “2026 SEPA”) with Yorkville. Under the 2026 SEPA, the Company has the right, but not the obligation, to sell to Yorkville up to $25.0 million of its Common Stock, subject to certain limitations and conditions set forth in the 2026 SEPA, from time to time over a 36-month period. Sales of Common Stock to Yorkville under the 2026 SEPA, and the timing of any such sales, are at the Company’s option.

 

Upon satisfaction of the conditions set forth in the 2026 SEPA, including the effectiveness of a resale registration statement covering the applicable shares, the Company may direct Yorkville to purchase a specified number of shares of Common Stock by delivering written notice (each, an “Advance”). An Advance may not exceed the greater of (i) 50,000 shares of Common Stock (as adjusted for the Reverse Stock Split) and (ii) 100% of the average daily trading volume of the Common Stock during the five trading days immediately preceding the Advance.

 

Yorkville will generally purchase shares pursuant to an Advance at a price per share equal to 97% of the Market Price, as defined in the 2026 SEPA. The Company may establish a minimum acceptable price for each Advance, below which the Company will not be obligated to sell shares to Yorkville.

 

The 2026 SEPA limits the number of shares that may be sold to Yorkville such that Yorkville and its affiliates may not beneficially own more than 4.99% of the Company’s outstanding voting power or number of shares of Common Stock. In addition, absent stockholder approval, the issuance of Common Stock under the 2026 SEPA is capped at 19.9% of the Company’s outstanding Common Stock as of July 1, 2026.

 

The 2026 SEPA will automatically terminate on the earlier of (i) the 36-month anniversary of the agreement or (ii) the date on which Yorkville has made payments for shares of Common Stock equal to the $25.0 million commitment amount. The Company may also terminate the 2026 SEPA upon five trading days’ prior written notice, subject to the conditions specified in the agreement.

 

The 2026 SEPA was accounted for as a liability under ASC 815 as it includes an embedded put option and an embedded forward option. The put option is recognized at inception and the forward option is recognized upon issuance of notice for the sale of the Company’s Common Stock.

 

The fair value of the derivative liability related to the embedded put option was estimated at $0.5 million at the inception of the agreement and $0.4 million as of September 30, 2026. The estimated issuance date fair value and remeasurement adjustment for the embedded put option is presented as a single line within other (income) expense, net in the accompanying condensed consolidated statements of operations under the caption change in fair value of 2026 SEPA derivative liabilities. The embedded forward option was deemed to have no value at September 30, 2026 as there were no outstanding notices for the sale of the Company’s Common Stock.

 

Subscription Agreements – Related Parties

 

Between February and September 2026, the Company entered into subscription agreements with two related party investors pursuant to which the Company agreed to issue and sell an aggregate of 413,059 shares of its Common Stock at prices between $5.80 and $9.30 per share. The Company received gross proceeds of approximately $3.1 million from the related party subscription agreements.

 

In October 2026, the Company issued 129,758 shares of common stock to a related party investor at a purchase price of $5.78 per share for aggregate proceeds of $0.8 million. The Company had received $0.3 million of the aggregate proceeds prior to September 30, 2026, which was recorded as a liability as of September 30, 2026, with the remaining $0.5 million received upon closing in October 2026.

 

ARC Forward Contract

 

As of September 30, 2026 and December 31, 2025, the Company had an outstanding forward contract to issue 124,065 shares of its Common Stock to ARC Group Limited for success fees earned from Data Knights in connection with the Business Combination. The forward contract was included in additional paid-in-capital in stockholders’ deficit in the condensed consolidated balance sheets as it met the criteria for equity accounting under ASC 815.

 

9. Net (Loss) Income per Share

 

Basic and diluted net (loss) income per share was calculated as follows:

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Numerator:                    
Net (loss) income  $(2,660)  $(741)  $(7,285)  $339 
Less: undistributed earnings attributable to participating warrant holders   -    -    -   $(35)
Net (loss) income attributable to common shareholders – basic  $(2,660)  $(741)  $(7,285)  $304 
Reallocation of undistributed earnings attributable to participating warrant holders   -   $-    -    1 
Net (loss) income attributable to common shareholders – diluted  $(2,660)  $(741)  $(7,285)  $305 
Denominator:                    
Weighted average shares of common stock outstanding – basic   6,148,636    5,261,803    5,837,487    4,125,372 
Net (loss) income per share attributable to common shares – basic  $(0.43)  $(0.14)  $(1.25)  $0.08 
Effect of dilutive securities                    
Restricted stock units   -    -    -    125,719 
Warrants   -    -    -    6,404 
Loan extensions   -    -    -    39,996 
Dilutive potential common shares   -    -    -    172,119 
Weighted average shares of common stock outstanding – diluted   6,148,636    5,261,803    5,837,487    4,297,491 
Net (loss) income per share attributable to common shares – diluted  $(0.43)  $(0.14)  $(1.25)  $0.08 

 

12

 

 

For the three and nine months ended September 30, 2026, and three months ended September 30, 2025, during which the Company recorded a net loss, all potentially dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share, and thus they are considered “anti-dilutive.” For these periods, the weighted average number of shares of Common Stock outstanding used to calculate both basic and diluted net loss per share of common stock is the same.

 

For the nine months ended September 30, 2025, the Company reported net income. For this period, net income is allocated to the participating warrants and the Common Stock based on their participation rights. Under the two-class method, basic net income per share is computed by dividing net income attributable to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. In addition, the dilutive effect of restricted stock units and warrants were calculated using the treasury stock method, whereby all such awards were assumed to be exercised at the beginning of the period. The hypothetical proceeds from such exercises, including the average unrecognized stock compensation expense for restricted stock units, were assumed to be used to purchase outstanding Common Stock at the average price during the period. The net share impact of dilutive securities was added to the weighted average basic common shares outstanding to calculate weighted average diluted shares outstanding.

 

The Company excluded the following potential shares of Common Stock, presented based on amounts outstanding at each period end, from the computation of diluted net (loss) income per share for the periods indicated because including them would have had an anti-dilutive effect:

 

   2026   2025   2026   2025 
   Three Months Ended
September 30,
   Nine Months Ended
September 30,
 
   2026   2025   2026   2025 
Restricted stock units   326,955    185,010    326,955    59,292 
Warrants for Common Stock   1,352,845    1,236,412    1,352,845    1,230,008 
Extension loans   -    34,087    -    - 
Total common stock equivalents   1,679,800    1,455,509    1,679,800    1,289,300 

 

10. Stock-Based Compensation

 

The Company recorded stock-based compensation expense in the following categories on the accompanying condensed consolidated statements of operations for the periods presented (in thousands):

 

    2026     2025     2026     2025  
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Cost of revenue   $ 23     $ 4     $ 57     $ 12  
General and administrative     331       132       1,026       518  
Sales and marketing     44       1       131       4  
Research and development     60       5       138       13  
Total stock-based compensation expense   $ 458     $ 142     $ 1,352     $ 547  

 

11. Stock Warrants

 

The Company has the following warrants outstanding for the periods presented:

 

 

    September 30, 2026     December 31, 2025  
    As of  
    September 30, 2026     December 31, 2025  
Liability Classified Warrants                
Business Combination Warrants     58,528       58,528  
PIPE Warrants     9,575       9,575  
Subtotal     68,103       68,103  
Equity Classified Warrants                
Public Warrants     1,150,000       1,150,000  
Private Placement Warrants     134,742       215,807  
Subtotal     1,284,742       1,365,807  
Grand Total     1,352,845       1,433,910  

 

13

 

 

On June 30, 2026, the Company issued 67,754 shares of Common Stock upon the partial exercise of pre-funded warrants and 13,310 shares of Common Stock upon the full exercise of warrants, both of which were originally issued in September 2024. The warrant exercise generated cash proceeds of approximately $0.04 million. As of September 30, 2026, no warrants or pre-funded warrants issued in connection with the September 2024 financing remained outstanding.

 

12. Fair Value Measurements

 

The following table presents the Company’s assets and liabilities that are measured at fair value on a recurring basis, inclusive of related party (in thousands):

 

   Level 1   Level 2   Level 3   Total 
   September 30, 2026 
   Level 1   Level 2   Level 3   Total 
Assets:                    
Money market funds  $35   $-   $-   $35 
Total assets, at fair value  $35   $-   $-   $35 
Liabilities:                    
Business Combination Warrants  $-   $-   $2   $2 
PIPE Warrants   -    -    3    3 
2026 SEPA put option liability   -    -    436    436 
Total liabilities, at fair value  $-   $-   $441   $441 

 

   Level 1   Level 2   Level 3   Total 
   December 31, 2025 
   Level 1   Level 2   Level 3   Total 
Assets:                    
Money market funds  $35   $-   $-   $35 
Bitcoin   506    -    -    506 
Total assets, at fair value  $541   $-   $-   $541 
Liabilities:                    
Business Combination Warrants  $-   $-   $60   $60 
PIPE Warrants   -    -    11    11 
2024 SEPA put option liability   -    -    186    186 
Total liabilities, at fair value  $-   $-   $257   $257 

 

Business Combination Warrants and PIPE Warrants

 

The following table presents the changes in the Business Combination Warrants and PIPE Warrants measured at fair value during the three and nine months ended September 30, 2026 (in thousands):

 

  

Business

Combination

Warrants

   PIPE Warrants 
Balance, December 31, 2025  $60   $11 
Changes in fair value   (14)   (2)
Balance, March 31, 2026  $46   $9 
Changes in fair value   (26)   (5)
Conversions to Common Stock          
Balance, June 30, 2026  $20   $4 
Changes in fair value   (18)   (1)
Balance, September 30, 2026  $2   $3 

 

14

 

 

The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at September 30, 2026 using the Black-Scholes option-pricing model with the following assumptions:

 

   Warrants   Warrants 
   As of September 30, 2026 
   PIPE   Business Combination 
   Warrants   Warrants 
Stock price  $5.79   $5.79 
Exercise price  $100.00   $115.00 
Expected volatility   103.5%   103.5%
Weighted average risk-free rate   4.8%   4.8%
Expected dividend yield   0.0%   0.0%
Expected term (in years)   2.1    2.1 

 

The Company remeasured the fair value of the Business Combination Warrants and PIPE Warrants at December 31, 2025 using the Black-Scholes option-pricing model with the following assumptions:

 

   Warrants   Warrants 
   As of December 31, 2025 
   PIPE   Business
Combination
 
   Warrants   Warrants 
Stock price  $11.00   $11.00 
Exercise price  $100.00   $115.0 
Expected volatility   85.0%   85.0%
Weighted average risk-free rate   3.5%   3.5%
Expected dividend yield   0.0%  0.0%
Expected term (in years)   2.85    2.85 

 

2024 SEPA Derivative Liability

 

The 2024 SEPA expired in June 2026. The following table presents the changes in the 2024 SEPA derivative liabilities measured at fair value during the nine months ended September 30, 2026 (in thousands):

 

    2024 SEPA Put Option     2024 SEPA Forward Option  
Balance, December 31, 2025   $ 186     $ -  
Changes in fair value     (186 )     (59 )
Conversions to Common Stock     -       59  
Balance, September 30, 2026   $ -     $ -  

 

The estimated fair value of the 2024 SEPA put option derivative liability was determined using a Monte Carlo simulation model in order to project the future path of the Company’s stock price over the commitment period with the following assumptions at December 31, 2025:

 

    As of  
    December 31, 2025  
Term (in years)     0.5  
Starting stock price   $ 11.0  
Expected volatility     144.0 %
Risk-free rate     3.6 %
         

 

15

 

 

The 2024 SEPA forward option liability was deemed to have no value at December 31, 2025 as there were no outstanding notices for the sale of the Company’s Common Stock.

 

The commitment period under the 2024 SEPA expired in June 2026, therefore, the 2024 SEPA derivative liability balances were $0 at September 30, 2026.

 

2026 SEPA Derivative Liability

 

The following table presents the changes in the 2026 SEPA derivative liabilities measured at fair value during the nine months ended September 30, 2026 (in thousands):

 

    2026 SEPA Put Option  
Balance, December 31, 2025   $ -  
Additions     478  
Changes in fair value     (42 )
Balance, September 30, 2026   $ 436  

 

The estimated fair value of the 2026 SEPA put option derivative liability was determined using a Monte Carlo simulation model in order to project the future path of the Company’s stock price over the commitment period with the following assumptions at September 30, 2026:

 

   As of 
   September 30, 2026 
Term (in years)   2.8 
Starting stock price  $5.79 
Expected volatility   141.8%
Risk-free rate   4.9%

 

16

 

 

The 2026 SEPA forward option liability was deemed to have no value at September 30, 2026 as there were no outstanding notices for the sale of the Company’s Common Stock.

 

13. Related Party Transactions

 

Conversion of Officer Accrued Salary – As described in Note 6, the Company issued 21,943 shares of Common Stock in exchange for the settlement of approximately $0.2 million of unpaid cash salary due to an officer and related party investor of the Company. See Note 6 for further details.

 

Subscription Agreements – As described in Note 8, the Company issued 413,059 shares of Common Stock in exchange for gross proceeds of $3.1 million pursuant to subscription agreements with two related party investors between February and September 2026. See Note 8 for further details.

 

In September 2026, the Company also received a $0.3 million advance from a related party investor in connection with a subscription for shares of Common Stock completed in October 2026. The advance was recorded as a liability as of September 30, 2026.

 

Accounting Services – The Company engages an accounting firm to provide accounting and bookkeeping services, which is majority owned by the Company’s Chief Financial Officer (“CFO”), who serves as an independent contractor to the Company.

 

For the three and nine months ended September 30, 2026, the Company incurred expenses of $0.02 million and $0.06 million, respectively, related to services provided by the CFO’s accounting firm. For the three and nine months ended September 30, 2025, the Company incurred expenses of $0.01 million and $0.02 million, respectively, related to services provided by the CFO’s accounting firm. Such amounts are included in general and administrative expenses in the accompanying condensed consolidated statements of operations.

 

As of September 30, 2026 and December 31, 2025, there were no amounts payable to the accounting firm.

 

Software Development Services – The Company engages a software development company to provide software development services, which is wholly owned by the Company’s Chief Technology Officer (“CTO”), who is an employee of the Company.

 

For the three and nine months ended September 30, 2026, the Company incurred expenses of $0.1 million and $0.2 million, respectively, for software development services provided by the CTO’s company. For the three and nine months ended September 30, 2025, the Company incurred expenses of $0.03 million and $0.2 million, respectively, for software development services provided by the CTO’s company. Such amounts are included in research and development expense in the accompanying condensed consolidated statements of operations.

 

As of September 30, 2026 and December 31, 2025, amounts payable to the CTO’s software development company were $0.1 million and $0.05 million, respectively, and are included in accounts payable and accrued expenses in the accompanying condensed consolidated balance sheets.

 

The Company believes that the terms of its arrangements with these vendors are consistent with those that would have been obtained from unaffiliated third parties.

 

14. Commitments and Contingencies

 

Lease Agreement

 

The Company has a month-to-month lease for a suite at a cost of $530 per month. The Company incurred $2 thousand and $6 thousand of rent expense, including common tenant costs, during each of the three and nine months ended September 30, 2026 and 2025.

 

17

 

 

Litigation

 

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recognized, if and when it is probable that a liability has been incurred and the amount can be reasonably estimated.

 

On November 6, 2025, ARC Group Limited and ARC Opportunity Fund Limited (together, “ARC”) filed a complaint against the Company and certain officers of the Company in the District Court of Minnesota, Fourth Judicial District (the “ARC complaint”). The ARC complaint alleges that the Company has breached certain contracts that the Company entered into with ARC before the closing of the Business Combination, including certain financial advisory contracts entered into by the Company at the direction of the sponsor of the Business Combination (the “sponsor”; the Company notes that the sponsor is an affiliate of ARC). Specifically, the ARC complaint asserts that the Company breached these contracts by issuing certain shares of Common Stock to ARC contemporaneously with the closing of the Business Combination and improperly cancelling those shares after the Business Combination as well as by failing to pay ARC certain cash amounts when due. The ARC complaint seeks an order of specific performance requiring the Company to reinstate the cancelled shares of Common Stock or, in the alternative, compensatory damages for such cancellation as well as payment of the other purported amounts due. The ARC complaint also asserts tort claims arising out of the Company’s actions and seeks compensatory damages (plus prejudgment interest) and punitive damages in connection with such claims but does not specify an amount of damages.

 

The Company notes that no shares of Common Stock were actually issued to ARC prior to or contemporaneously with the closing of the Business Combination and that, as of September 30, 2026 and as previously disclosed on the Form 10-K for the fiscal year ended December 31, 2025, the Company has recorded a forward contract to issue 124,065 shares of its Common Stock to ARC for success fees earned in connection with the Business Combination. As of September 30, 2026 and December 31, 2025, the Company has recorded aggregate cash liabilities payable to ARC equal to $0.4 million. The Company believes that the claim as asserted is overstated, and denies liability with respect to all disputed amounts and intends to defend itself vigorously. The Company is also assessing whether there are any counterclaims available to it arising out of self-dealing transactions between ARC and the sponsor. Accordingly, the Company has not recorded any additional liability arising out of the ARC complaint as the Company does not believe any incremental loss is probable, and the Company cannot estimate any reasonably possible loss or range of possible loss. On March 19, 2026, ARC voluntarily dismissed the complaint without prejudice.

 

The Company was not subject to any other material legal proceedings during the nine months ended September 30, 2026.

 

15. Subsequent Events

 

The Company has evaluated subsequent events occurring through November 16, 2026, the date the condensed consolidated financial statements were issued, for events requiring recording or disclosure in the Company’s condensed consolidated financial statements.

 

In October 2026, the Company entered into subscription agreements with two related party investors pursuant to which the Company agreed to issue and sell an aggregate of 174,884 shares of its Common Stock at prices between $5.54 and $5.78 per share. The Company received gross proceeds of approximately $1.0 million from the related party subscription agreements.

 

18

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis are intended to help you understand our business, financial condition, results of operations, liquidity, and capital resources. You should read this discussion in conjunction with the Company’s consolidated financial statements and related notes included elsewhere in this Report and in the Form 10-K.

 

In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading “Cautionary Note Regarding Forward-Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, risks and uncertainties, including those set forth under “Risk Factors” included elsewhere (or incorporated by reference) in this Report and in the Form 10-K. Unless the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “OneMedNet”, “we”, “us”, “our,” and “the Company” are intended to mean the business and operations of OneMedNet Corporation and its consolidated subsidiary following the completion of the business combination on November 7, 2023 involving OneMedNet Solutions Corporation (formerly named OneMedNet Corporation) (“Legacy ONMD”), with Legacy ONMD surviving as a wholly owned subsidiary of Data Knights Acquisition Corp. (“Data Knights”) (the “Business Combination”).

 

Company Overview

 

We are a healthcare technology company focused on the acquisition, curation, de-identification and commercialization of real-world clinical data. Through our proprietary iRWD™ platform and network of healthcare providers, we provide pharmaceutical companies, medical device manufacturers, contract research organizations, academic institutions and artificial intelligence developers with access to longitudinal, multimodal clinical datasets for use in research, product development, regulatory submissions and real-world evidence generation.

 

Our platform identifies, de-identifies and curates clinical data obtained from healthcare providers, including electronic health records, clinical notes, medical imaging, laboratory results and other clinical information. We combine our technology, healthcare provider network and clinical expertise to develop fit-for-purpose datasets based on customer-specific requirements.

 

Reverse Stock Split

 

At the Company’s 2026 annual meeting of stockholders held on September 18, 2026, the Company’s stockholders approved a proposal to effect a reverse stock split of the Company’s common stock by a ratio ranging from any whole number between 1-for-5 and 1-for-20, as determined by the Board of Directors in its discretion.

 

On September 29, 2026, the Company effected a 1-for-10 reverse stock split of the Company’s common stock, par value $0.0001 per share (“Common Stock”) (the “Reverse Stock Split”). As a result of the Reverse Stock Split, every 10 shares of the Company’s Common Stock issued and outstanding were automatically converted into one new share of Common Stock. Proportionate adjustments were also made to the number of shares available under the Company’s equity incentive plans and the exercise price and number of shares underlying outstanding restricted stock units, warrants, and other equity awards. The Reverse Stock Split did not decrease the number of authorized shares of Common Stock and preferred stock or otherwise affect the par value of the Common Stock. No fractional shares were issued in connection with the Reverse Stock Split and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share for stockholders of record who would be entitled to receive fractional shares pursuant to the Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Company effecting the Reverse Stock Split.

 

All information presented herein, unless otherwise indicated herein, reflects the Reverse Stock Split of the Company’s outstanding shares of common stock, and unless otherwise indicated, all such amounts and corresponding conversion price or exercise price data set forth herein have been adjusted to give effect to such Reverse Stock Split.

 

Nasdaq Compliance

 

On April 14, 2026, the Company received notice from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company, based on the closing bid price of the shares of Common Stock for the last 30 consecutive business days, is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 12, 2026, to regain compliance with the Bid Price Rule. To regain compliance, the minimum bid price of the shares of Common Stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period.

 

On October 13, 2026, we received a letter from Nasdaq notifying us that we had regained compliance with the Bid Price Rule and accordingly, the matter is now closed.

 

Key Components of Consolidated Statements of Operations

 

Revenue

 

The Company generates revenue from its iRWD platform, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and AI markets. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered and accepted by the customer. The Company’s legacy BEAM platform was decommissioned in May 2025, and no revenue was generated from this platform thereafter.

 

19

 

 

The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advance billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable are recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.

 

Cost of Revenue

 

Our cost of revenue consists primarily of (i) software and hosting costs associated with operating our real-world data platform, (ii) data costs, which include amounts paid to data partners to acquire the clinical and imaging data we deliver to customers, and (iii) personnel costs for employees directly involved in curating and delivering data.

 

General and Administrative

 

General and administrative functions include finance, legal, operations, human resources, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.

 

Research and Development

 

Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.

 

Sales and Marketing

 

Our sales and marketing costs consist of labor and tradeshow costs.

 

Other (Income) Expenses, Net

 

Interest Expense

 

Interest expense consists of interest incurred on our outstanding debt facilities, including loans with related parties, deferred underwriter fees and insurance premiums paid in exchange for a note payable.

 

Change in Fair Value of Warrants

 

We have outstanding warrants that were issued at the closing of the Business Combination, which are accounted for as liabilities at fair value. These warrants are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations.

 

Change in Fair Value of Convertible Notes

 

We have elected the fair value option of accounting for the PIPE Notes (as defined in the Form 10-K) issued in the Business Combination and the Yorkville Note (as defined in the Form 10-K) issued with the 2024 SEPA. These instruments contained embedded derivatives that would require bifurcation and separate accounting; therefore, we made the election to measure the entire contingently convertible debt instruments, including accrued interest, at fair value. These instruments are subsequently re-measured at fair value on our consolidated balance sheets at the end of each reporting period and at settlement, as applicable, and changes in fair value are recognized in the consolidated statements of operations. The PIPE Notes and Yorkville Note were both settled in 2025 and were no longer outstanding as of December 31, 2025.

 

20

 

 

Change in Fair Value of Crypto Assets – Bitcoin

 

We previously adopted a Bitcoin strategy on the balance sheets as a forward-looking approach to corporate treasury management that incorporates digital currencies. Our Bitcoin holdings were held at fair value on the consolidated balance sheets and are re-measured at the end of each reporting period based on the quoted end-of-day price provided by a reputable and liquid exchange. As of September 30, 2026, we no longer hold Bitcoin or any other crypto assets.

 

Realized Loss (Gain) on Sale of Crypto Assets – Bitcoin

 

As part of our Bitcoin strategy, we routinely sell quantities held as part of our corporate treasury strategy to fund operations as needed. We recognize a realized gain upon sale when the price of Bitcoin is higher than its initial purchase price.

 

Change in Fair Value of SEPA Derivative Liabilities

 

We entered into the 2024 SEPA and 2026 SEPA, which provide us with the right, but not the obligation, to require Yorkville to purchase shares of our Common Stock during the respective commitment periods, subject to certain limitations. We recognize a put option liability upon execution of each SEPA and a forward option liability upon delivery of a notice to sell shares of our Common Stock. These derivative liabilities are subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in our consolidated statements of operations.

 

Results of Operations

 

Comparison of the Three Months Ended September 30, 2026 and 2025

 

The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):

 

   Three Months Ended September 30,   Change 
   2026   2025   $   % 
Revenue                    
Data delivery revenue   1,023    177    846    478%
Total revenue   1,023    177    846    478%
Cost of revenue   1,386    399    987    247%
Gross margin   (363)   (222)   (141)   64%
Operating expenses                    
General and administrative   1,185    1,386    (201)   -15%
Sales and marketing   262    304    (42)   -14%
Research and development   424    323    101    31%
Total operating expenses   1,871    2,013    (142)   -7%
Loss from operations   (2,234)   (2,235)   1    -0%
Other (income) expense, net                    
Interest expense   8    6    2    33%
Change in fair value of warrants   (19)   20    (39)   -195%
Change in fair value of crypto assets – Bitcoin   -    (55)   55    -100%
Realized gain on sale of crypto assets – Bitcoin   -    (54)   54    -100%
Change in fair value of 2024 SEPA derivative liabilities   -    402    (402)   -100%
Change in fair value of 2026 SEPA derivative liabilities   436    -    436    100%
Gain on troubled debt restructurings   -    (1,862)   1,862    -100%
Loss on extinguishment of debt   -    41    (41)   -100%
Other expense, net   1    8    (7)   -88%
Total other expense (income), net   426    (1,494)   1,920    -129%
Net (loss) income  $(2,660)  $(741)  $(1,919)   -259%

 

21

 

 

Revenue

 

Total revenue increased by $0.8 million, or 478%, during the three months ended September 30, 2026, compared to the three months ended September 30, 2025. The increase was attributable to a $0.8 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes.

 

Cost of Revenue

 

Cost of revenue was $1.4 million for the three months ended September 30, 2026, compared to $0.4 million for the three months ended September 30, 2025, an increase of $1.0 million, or 247%. The increase was primarily driven by a $0.5 million increase in software and hosting costs associated with operating and scaling the Company’s AI-enabled real-world data platform, a $0.4 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.1 million increase in personnel costs due to headcount growth.

 

General and Administrative

 

General and administrative expenses were $1.2 million for the three months ended September 30, 2026, compared to $1.4 million for the three months ended September 30, 2025, a decrease of $0.2 million, or 15%. The decrease was primarily attributable to a $0.4 million decrease in professional fees, largely due to lower consulting and legal costs, which is partially offset by a $0.2 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026,

 

Sales and Marketing

 

Sales and marketing expenses for the three months ended September 30, 2026, were generally consistent with sales and marketing expenses for the three months ended September 30, 2025.

 

Research and Development

 

Research and development expenses were $0.4 million for the three months ended September 30, 2026, compared to $0.3 million for the three months ended September 30, 2025, an increase of $0.1 million, or 31%. The increase was primarily attributable to a $0.1 million increase in share-based compensation expense related to equity awards granted during the second half of 2025 and 2026.

 

Interest Expense

 

Interest expense for the three months ended September 30, 2026 was generally consistent with interest expense for the three months ended September 30, 2025.

 

22

 

 

Change in Fair Value of Warrants

 

The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.

 

Change in Fair Value of Crypto Assets – Bitcoin

 

The change in fair value of crypto assets – Bitcoin during the three months ended September 30, 2025, reflected fluctuations in the price of Bitcoin. There was no corresponding change in fair value during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.

 

Realized Gain on Sale of Crypto Assets – Bitcoin

 

The realized gain on sale of crypto assets – Bitcoin during the three months ended September 30, 2025, reflected the difference between the carrying value of Bitcoin and its market price upon sale. There was no corresponding realized gain during the three months ended September 30, 2026, as we liquidated all of our Bitcoin holdings during the second quarter of 2026.

 

Change in Fair Value of SEPA Derivative Liabilities

 

The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company’s projected stock price over the applicable commitment period. The change in fair value during the three months ended September 30, 2026, related to the 2026 SEPA, while the change in fair value during the three months ended September 30, 2025, related to the 2024 SEPA.

 

Gain on Troubled Debt Restructurings

 

Gain on troubled debt restructurings during the three months ended September 30, 2025 was primarily driven by restructured trade payables with two separate vendors which resulted in a gain of $1.9 million. During the three months ended September 30, 2026, we did not restructure any of our debt or trade payables.

 

Comparison of the Nine Months Ended September 30, 2026 and 2025

 

The following table sets forth our condensed consolidated statements of operations data for the periods presented (in thousands):

 

   Nine Months Ended September 30,   Change 
   2026   2025   $   % 
Revenue                    
Subscription revenue  $-   $105   $(105)   -100%
Data delivery revenue   1,410    363    1,047    288%
Total revenue   1,410    468    942    201%
Cost of revenue   2,928    1,136    1,792    158%
Gross margin   (1,518)   (668)   (850)   127%
Operating expenses                    
General and administrative   3,439    3,999    (560)   -14%
Sales and marketing   1,031    846    185    22%
Research and development   1,059    1,072    (13)   -1%
Total operating expenses   5,529    5,917    (388)   -7%
Loss from operations   (7,047)   (6,585)   (462)   7%
Other (income) expense, net                    
Interest expense   27    59    (32)   -54%
Change in fair value of warrants   (66)   23    (89)   -387%
Change in fair value of convertible notes   -    (1,285)   1,285    -100%
Change in fair value of crypto assets – Bitcoin   (147)   782    (929)   -119%
Realized loss (gain) on sale of crypto assets – Bitcoin   234    (899)   1,133    -126%
Change in fair value of 2024 SEPA derivative liabilities   (245)   (32)   (213)   666%
Change in fair value of 2026 SEPA derivative liabilities   436    -    436    100%
Gain on troubled debt restructurings   -    (5,569)   5,569    -100%
Loss on extinguishment of debt   -    41    (41)   -100%
Other (income) expense, net   (1)   (44)   43    -98%
Total other (income) expense, net   238    (6,924)   7,162    -103%
Net (loss) income  $(7,285)  $339   $(7,624)   -2249%

 

23

 

 

Revenue

 

Total revenue increased by $0.9 million, or 201%, during the nine months ended September 30, 2026, compared to the nine months ended September 30, 2025. The increase was primarily attributable to a $1.0 million increase in data delivery revenue as the Company continued its transition to a unified RWD platform, driving increased customer adoption and higher data delivery volumes. This growth was partially offset by a $0.1 million decrease in subscription revenue due to the decommissioning of the BEAM platform in May 2025.

 

Cost of Revenue

 

Cost of revenue was $2.9 million for the nine months ended September 30, 2026, compared to $1.1 million for the nine months ended September 30, 2025, an increase of $1.8 million, or 158%. The increase was primarily driven by a $1.1 million increase in software and hosting costs associated with operating and scaling the Company’s AI-enabled real-world data platform, a $0.5 million increase in iRWD costs to support higher data delivery revenue through the iRWD platform, and a $0.2 million increase in personnel costs due to headcount growth.

 

General and Administrative

 

General and administrative expenses were $3.4 million for the nine months ended September 30, 2026, compared to $4.0 million for the nine months ended September 30, 2025, representing a decrease of $0.6 million, or 14%. The decrease was primarily attributable to a $1.0 million reduction in professional fees, primarily due to lower legal, consulting, and other professional service costs, and a $0.1 million decrease in other general and administrative expenses. These decreases were partially offset by a $0.5 million increase in share-based compensation expense related to equity awards granted during 2025 and 2026 and a $0.1 million increase in salaries and related personnel costs resulting from headcount growth.

 

Sales and Marketing

 

Sales and marketing expenses were $1.0 million for the nine months ended September 30, 2026, compared to $0.8 million for the nine months ended September 30, 2025, representing an increase of $0.2 million, or 22%. The increase was primarily attributable to a $0.1 million increase in personnel costs due to headcount growth and a $0.1 million increase in consulting costs resulting from business development initiatives intended to support growth of the Company’s iRWD platform.

 

Research and Development

 

Research and development expenses for the nine months ended September 30, 2026, were generally consistent with research and development expenses for the nine months ended September 30, 2025.

 

24

 

 

Interest Expense

 

Interest expense for the nine months ended September 30, 2026 was generally consistent with interest expense for the nine months ended September 30, 2025.

 

Change in Fair Value of Warrants

 

The change in fair value of warrants is composed of the re-measurement adjustment for our liability-classified warrants that were issued in connection with the Business Combination. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock.

 

Change in Fair Value of Convertible Notes

 

The change in fair value of convertible notes is composed of the re-measurement adjustment for the PIPE Notes and Yorkville Note which are carried at fair value. The change is mainly due to the resulting fluctuations in the market price of shares of Common Stock. Both instruments were converted or repaid in the second quarter of 2025; therefore, no re-measurement adjustment was required for the nine months ended September 30, 2026.

 

Change in Fair Value of Crypto Assets – Bitcoin

 

The change in fair value of crypto assets – Bitcoin during the nine months ended September 30, 2026 and 2025 reflected fluctuations in the price of Bitcoin.

 

Realized Loss (Gain) on Sale of Crypto Assets – Bitcoin

 

The realized loss (gain) on sale of crypto assets – Bitcoin during the nine months ended September 30, 2026 and 2025 reflected the difference between the carrying value of Bitcoin and its market price upon sale.

 

Change in Fair Value of SEPA Derivative Liabilities

 

The change in fair value of SEPA derivative liabilities is primarily driven by assumptions regarding the expected timing and volume of Common Stock sales to Yorkville and the Company’s projected stock price over the applicable commitment period. For the nine months ended September 30, 2026, the change in fair value included amounts related to both the 2024 SEPA and the 2026 SEPA, whereas the change in fair value for the nine months ended September 30, 2025, related solely to the 2024 SEPA.

 

Gain on Troubled Debt Restructurings

 

Gain on troubled debt restructurings during the nine months ended September 30, 2025 was primarily driven by our settlement of deferred underwriter fees which resulted in a gain of $2.8 million. In addition, we restructured trade payables with five separate vendors leading to an additional gain of $2.8 million. During the nine months ended September 30, 2026, we did not restructure any of our debt or trade payables.

 

Liquidity and Capital Resources

 

As of September 30, 2026, our principal sources of liquidity were proceeds from related party investors and the 2024 SEPA.

 

The following table shows net cash and cash equivalents used in operating activities, net cash and cash equivalents used in investing activities, and net cash and cash equivalents provided by financing activities during the periods presented:

 

   Nine Months Ended September 30, 
   2026   2025 
Net cash provided by (used in)          
Operating activities  $(4,839)  $(5,455)
Investing activities   407    2,358 
Financing activities   3,984    3,074 

 

25

 

 

Operating Activities

 

Our net cash and cash equivalents used in operating activities consists of net loss adjusted for certain non-cash items, including depreciation and amortization, stock-based compensation expense, changes in fair value of liability classified financial instruments, as well as changes in operating assets and liabilities. The primary changes in working capital items, such as the changes in accounts receivable and deferred revenue, result from the difference in timing of payments from our customers related to contract performance obligation. This may result in an operating cash flow source or use for the period, depending on the timing of payments received as compared to the fulfillment of the performance obligation.

 

During the nine months ended September 30, 2026, we used $4.8 million of cash in operating activities, primarily resulting from our net loss of $7.3 million, offset by non-cash charges of $1.6 million and cash provided by changes in our operating assets and liabilities of $0.9 million.

 

During the nine months ended September 30, 2025, we used $5.5 million of cash in operating activities, primarily resulting from non-cash charges of $6.3 million, offset by our net income of $0.3 million and cash provided by changes in our operating assets and liabilities of $0.5 million.

 

Investing Activities

 

Our investing activities have consisted primarily of property and equipment purchases and Bitcoin purchases and sales.

 

During the nine months ended September 30, 2026, net cash provided by investing activities was $0.4 million, primarily consisting of proceeds from Bitcoin sales of $0.4 million.

 

During the nine months ended September 30, 2025, net cash provided by investing activities was $2.4 million, primarily consisting of proceeds from Bitcoin sales of $4.8 million offset by Bitcoin purchases of $2.4 million.

 

Financing Activities

 

During the nine months ended September 30, 2026, net cash provided by financing activities was $4.0 million, consisting of $3.4 million in net proceeds from related party investments and $1.0 million in net proceeds from the 2024 SEPA, partially offset by debt repayments of $0.4 million.

 

During the nine months ended September 30, 2025, net cash provided by financing activities was $3.1 million, consisting of $1.7 million in net proceeds from related party investments and $2.5 million in net proceeds from private placements, partially offset by aggregate repayments of $1.1 million of debt and deferred underwriter fees.

 

Contractual Obligations and Commitments and Going Concern Outlook

 

Currently, management does not believe that our cash and cash equivalents are sufficient to meet our foreseeable cash needs for at least the next 12 months. Our foreseeable cash needs, in addition to our recurring operating expenses, include our expected capital expenditures to support the expansion of our infrastructure and workforce, interest expense and minimum contractual obligations. Management intends to raise cash for operations through debt and equity offerings. As a result of the Company’s recurring loss from operations and the need for additional financing to fund its operating and capital requirements there is uncertainty regarding the Company’s ability to maintain liquidity sufficient to operate its business effectively, which raises substantial doubt as to the Company’s ability to continue as a going concern.

 

Our future capital requirements will depend on many factors, including our growth rate, the timing and extent of spending to support research and development efforts, the expansion of sales and marketing activities, the introduction of new and enhanced product and service offerings, and the cost of any future acquisitions of technology or businesses. In the event that additional financing is required from outside sources, we may be unable to raise the funds on acceptable terms, if at all.

 

26

 

 

The following table summarizes our material cash requirements as of September 30, 2026:

 

       Payments due in: 
   Total   Less than 1 year   1-3 years 
Accounts payable & accrued expenses  $4,504   $4,504   $- 
Loans payable   563    464    99 
   $5,067   $4,968   $99 

 

Critical Accounting Policies and Estimates

 

Our management’s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements which have been prepared in accordance with GAAP. In preparing our financial statements, we make estimates, assumptions, and judgments that can have a significant impact on our reported revenue, results of operations, and net income or loss, as well as on the value of certain assets and liabilities on our balance sheet during and as of the reporting periods. These estimates, assumptions, and judgments are necessary because future events and their effects on our results of operations and the value of our assets cannot be determined with certainty and are made based on our historical experience and on other assumptions that we believe to be reasonable under the circumstances. These estimates may change as new events occur or additional information is obtained, and we may periodically be faced with uncertainties, the outcomes of which are not within our control and may not be known for a prolonged period of time. Because the use of estimates is inherent in the financial reporting process, actual results could differ from those estimates.

 

For a discussion of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Form 10-K, the notes to our audited financial statements appearing in the Form 10-K, and the notes to the financial statements appearing elsewhere in this Report. Except as described in this Report, there have been no material changes to these critical accounting policies and estimates through September 30, 2026 from those discussed in the Form 10-K.

 

Recently Issued and Adopted Accounting Pronouncements

 

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements included elsewhere in this Report.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act), as of September 30, 2026. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were ineffective due to material weaknesses in our internal controls over financial reporting related to user access and segregation of duties, the lack of a formalized control environment and oversight of controls over financial reporting, and revenue recognition.

 

27

 

 

Material Weaknesses

 

Management is aware of material weaknesses in the Company’s internal control related to user access/segregation of duties, lack of a formalized control environment and oversight of controls over financial reporting and revenue recognition. Due to the limited transactional volume currently experienced, combined with our financial limitations, we do not currently have an expanded accounting department that would allow us to better segregate duties. Over time, as we continue to grow and add accounting staff, we expect to continue to enhance our internal control structure, including appropriate segregation of duties. Management has begun taking remediation steps to address the material weaknesses, including the hiring of a full-time controller in July 2025 and adding additional review procedures over our financial records. This remediation is an ongoing process and there can be no assurance that it will effectively address the material weaknesses.

 

Changes in Internal Control Over Financial Reporting

 

Except as described above, there were no other changes in our internal control over financial reporting during the three months ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

PART II – OTHER INFORMATION

 

Item 1. Legal Proceedings.

 

For information regarding litigation, see Part I – Item 1. Condensed Consolidated Financial Statements, Note 14 - Commitments and Contingencies.

 

Item 1A. Risk Factors.

 

In addition to the other information set forth in this Report, you should carefully consider the factors discussed in the “Risk Factors” in the Form 10-K and our other public filings, which could materially affect our business, financial condition or future results. There have been no material changes from risk factors previously disclosed in “Risk Factors” in the Form 10-K and our other public filings.

 

28

 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. 

 

The Company entered into a subscription agreement, dated July 30, 2026, with Dr. Thomas Kosasa, a director and related party of the Company, pursuant to which the Company issued 144,928 shares of Common Stock to Dr. Kosasa at a price of $6.90 per share. The Company received net proceeds of approximately $1,000,000 from the related party subscription agreement. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act.

 

The Company entered into a subscription agreement, dated September 10, 2026, with Dr. Jeffrey Yu, a director, officer and related party of the Company, pursuant to which the Company issued 14,286 shares of Common Stock to Dr. Yu at a price of $6.30 per share. The Company received net proceeds of approximately $90,000 from the related party subscription agreement. These shares were issued in reliance on the exemption from registration provided by Section 4(a)(2) under the Securities Act.

 

Except as set forth above, during the three months ended September 30, 2026, we did not have issuances of unregistered securities not previously included in a Current Report on Form 8-K.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

Not applicable.

 

Item 5. Other Information.

 

During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

Item 6. Exhibits.

 

The following documents are included as exhibits to this Report:

 

Exhibit Number   Description
3.1   Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on November 13, 2023).
3.2   Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of OneMedNet Corporation (incorporated by reference to Exhibit 3.1 to the Company’s Form 8-K, filed with the SEC on September 29, 2026).
3.3   Amended and Restated Bylaws of OneMedNet Corporation (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the SEC on November 13, 2023).
10.1   Standby Equity Purchase Agreement, dated as of July 1, 2026, by and between OneMedNet Corporation and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on July 1, 2026).
10.2*   OneMedNet Corporation Amended and Restated 2022 Equity Incentive Plan.
31.1*   Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*   Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1#   Certification of Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2#   Certification of Chief Financial Officer (Principal Financial Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

 

* Filed herewith.

 

# The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed to accompany this Report and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

 

29

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on November 16, 2026.

 

  OneMedNet Corporation
     
  By: /s/ Robert Golden
    Robert Golden
    Chief Financial Officer
    (Duly Authorized Officer and Principal Financial and Accounting Officer)

 

30

 

Keep reading